Sorafenib Tosylate APIs, provided by Loncom Pharma, are integral in creating multi-kinase inhibitors for treating advanced liver, kidney, and thyroid cancers. These APIs disrupt cancer cell signaling and angiogenesis, offering a lifeline to patients with hard-to-treat tumors.
